In the first quarter of 2013, Aegerion Pharmaceuticals (AEGR) posted its first revenues ever. At its recent price of about $74, the company's shares are trading at about 1,732 times trailing twelve month sales. If you think that's a bit steep for a biotech with a single product, you're not alone.
I'm going to show you why this company's lone product, recently approved in the US for the treatment of one ultra-rare disease, makes Aegerion's recent price seem not just reasonable, but undervalued.
Good news from the EU
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: